---
title: "Shanghai Serum Bio-Technology Co., Ltd. (688163.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/688163.SH.md"
symbol: "688163.SH"
name: "Shanghai Serum Bio-Technology Co., Ltd."
industry: "Biotechnology"
---

# Shanghai Serum Bio-Technology Co., Ltd. (688163.SH)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | CN Market |
| Website | [www.serum-china.com.cn](https://www.serum-china.com.cn) |

## Company Profile

Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sales of antitoxin and antiserum products in China. It offers equine anti-tetanus immunoglobulin, anti-venin, and anti-rabies serum products. The company was founded in 1999 and is based in Shang...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-15T04:30:09.000Z

**Overall: C (0.46)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 57 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.27% |  |
| Net Profit YoY | -10.55% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.50 |  |
| Dividend Ratio | 1.23% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2.81B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 196.56M |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.07% | C |
| Profit Margin | 23.15% | A |
| Gross Margin | 80.60% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.27% | D |
| Net Profit YoY | -10.55% | D |
| Total Assets YoY | 1.40% | C |
| Net Assets YoY | 0.98% | C |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 431.94% | C |
| OCF YoY | -0.27% | D |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.17 | D |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 3.14% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Serum Bio-Technology Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.07%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "23.15%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "80.60%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.27%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-10.55%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.40%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.98%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "431.94%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-0.27%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.17",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "3.14%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | BeOne Medicines (SH.688235) | C | A | B | C | A | B |
| 02 | Gan & Lee (SH.603087) | B | B | D | A | B | B |
| 03 | Sunshine Guojian Pharmaceutical (SH.688336) | A | B | D | B | C | B |
| 04 | Biocytogen (SH.688796) | A | A | C | D | B | B |
| 05 | BTBP (SH.600161) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 61.84 | 26/83 | 58.23 | 53.24 | 39.92 |
| PB | 2.50 | 34/83 | 2.40 | 2.17 | 1.76 |
| PS (TTM) | 14.32 | 58/83 | 13.47 | 12.32 | 9.91 |
| Dividend Yield | 1.23% | 22/83 | 1.78% | 1.43% | 1.30% |

## References

- [Company Overview](https://longbridge.com/en/quote/688163.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/688163.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/688163.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.